Literature DB >> 27260156

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.

Andrew J Aguirre1, Robin M Meyers2, Barbara A Weir3, Francisca Vazquez3, Cheng-Zhong Zhang3, Uri Ben-David2, April Cook3, Gavin Ha3, William F Harrington2, Mihir B Doshi3, Maria Kost-Alimova2, Stanley Gill3, Han Xu2, Levi D Ali2, Guozhi Jiang2, Sasha Pantel2, Yenarae Lee2, Amy Goodale2, Andrew D Cherniack2, Coyin Oh2, Gregory Kryukov3, Glenn S Cowley2, Levi A Garraway4, Kimberly Stegmaier5, Charles W Roberts6, Todd R Golub7, Matthew Meyerson8, David E Root2, Aviad Tsherniak9, William C Hahn10.   

Abstract

UNLABELLED: The CRISPR/Cas9 system enables genome editing and somatic cell genetic screens in mammalian cells. We performed genome-scale loss-of-function screens in 33 cancer cell lines to identify genes essential for proliferation/survival and found a strong correlation between increased gene copy number and decreased cell viability after genome editing. Within regions of copy-number gain, CRISPR/Cas9 targeting of both expressed and unexpressed genes, as well as intergenic loci, led to significantly decreased cell proliferation through induction of a G2 cell-cycle arrest. By examining single-guide RNAs that map to multiple genomic sites, we found that this cell response to CRISPR/Cas9 editing correlated strongly with the number of target loci. These observations indicate that genome targeting by CRISPR/Cas9 elicits a gene-independent antiproliferative cell response. This effect has important practical implications for the interpretation of CRISPR/Cas9 screening data and confounds the use of this technology for the identification of essential genes in amplified regions. SIGNIFICANCE: We found that the number of CRISPR/Cas9-induced DNA breaks dictates a gene-independent antiproliferative response in cells. These observations have practical implications for using CRISPR/Cas9 to interrogate cancer gene function and illustrate that cancer cells are highly sensitive to site-specific DNA damage, which may provide a path to novel therapeutic strategies. Cancer Discov; 6(8); 914-29. ©2016 AACR.See related commentary by Sheel and Xue, p. 824See related article by Munoz et al., p. 900This article is highlighted in the In This Issue feature, p. 803. 2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27260156      PMCID: PMC4972686          DOI: 10.1158/2159-8290.CD-16-0154

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  48 in total

Review 1.  Genome editing with engineered zinc finger nucleases.

Authors:  Fyodor D Urnov; Edward J Rebar; Michael C Holmes; H Steve Zhang; Philip D Gregory
Journal:  Nat Rev Genet       Date:  2010-09       Impact factor: 53.242

2.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease.

Authors:  Seung Woo Cho; Sojung Kim; Jong Min Kim; Jin-Soo Kim
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

Review 3.  High-throughput functional genomics using CRISPR-Cas9.

Authors:  Ophir Shalem; Neville E Sanjana; Feng Zhang
Journal:  Nat Rev Genet       Date:  2015-04-09       Impact factor: 53.242

Review 4.  Timeline: Chemotherapy and the war on cancer.

Authors:  Bruce A Chabner; Thomas G Roberts
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

5.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors:  David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

6.  Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability.

Authors:  Yotam Drier; Michael S Lawrence; Scott L Carter; Chip Stewart; Stacey B Gabriel; Eric S Lander; Matthew Meyerson; Rameen Beroukhim; Gad Getz
Journal:  Genome Res       Date:  2012-11-02       Impact factor: 9.043

7.  RNA-programmed genome editing in human cells.

Authors:  Martin Jinek; Alexandra East; Aaron Cheng; Steven Lin; Enbo Ma; Jennifer Doudna
Journal:  Elife       Date:  2013-01-29       Impact factor: 8.140

8.  Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.

Authors:  Albert W Cheng; Haoyi Wang; Hui Yang; Linyu Shi; Yarden Katz; Thorold W Theunissen; Sudharshan Rangarajan; Chikdu S Shivalila; Daniel B Dadon; Rudolf Jaenisch
Journal:  Cell Res       Date:  2013-08-27       Impact factor: 25.617

9.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors.

Authors:  Pablo Perez-Pinera; D Dewran Kocak; Christopher M Vockley; Andrew F Adler; Ami M Kabadi; Lauren R Polstein; Pratiksha I Thakore; Katherine A Glass; David G Ousterout; Kam W Leong; Farshid Guilak; Gregory E Crawford; Timothy E Reddy; Charles A Gersbach
Journal:  Nat Methods       Date:  2013-07-25       Impact factor: 28.547

10.  Optical control of mammalian endogenous transcription and epigenetic states.

Authors:  Silvana Konermann; Mark D Brigham; Alexandro Trevino; Patrick D Hsu; Matthias Heidenreich; Le Cong; Randall J Platt; David A Scott; George M Church; Feng Zhang
Journal:  Nature       Date:  2013-08-23       Impact factor: 49.962

View more
  209 in total

1.  Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.

Authors:  Teng Fei; Yiwen Chen; Tengfei Xiao; Wei Li; Laura Cato; Peng Zhang; Maura B Cotter; Michaela Bowden; Rosina T Lis; Shuang G Zhao; Qiu Wu; Felix Y Feng; Massimo Loda; Housheng Hansen He; X Shirley Liu; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-13       Impact factor: 11.205

Review 2.  Genomic evolution of cancer models: perils and opportunities.

Authors:  Uri Ben-David; Rameen Beroukhim; Todd R Golub
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

3.  CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.

Authors:  Ajinkya Patil; Mark Manzano; Eva Gottwein
Journal:  Blood       Date:  2018-06-28       Impact factor: 22.113

4.  Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.

Authors:  Edwin H Yau; Indrasena Reddy Kummetha; Gianluigi Lichinchi; Rachel Tang; Yunlin Zhang; Tariq M Rana
Journal:  Cancer Res       Date:  2017-09-27       Impact factor: 12.701

5.  Is microfluidics the "assembly line" for CRISPR-Cas9 gene-editing?

Authors:  Fatemeh Ahmadi; Angela B V Quach; Steve C C Shih
Journal:  Biomicrofluidics       Date:  2020-11-24       Impact factor: 2.800

6.  Common pitfalls in preclinical cancer target validation.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2017-05-19       Impact factor: 60.716

7.  Improved design and analysis of CRISPR knockout screens.

Authors:  Chen-Hao Chen; Tengfei Xiao; Han Xu; Peng Jiang; Clifford A Meyer; Wei Li; Myles Brown; X Shirley Liu
Journal:  Bioinformatics       Date:  2018-12-01       Impact factor: 6.937

8.  Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus.

Authors:  Ping Gao; Ji-Han Xia; Csilla Sipeky; Xiao-Ming Dong; Qin Zhang; Yuehong Yang; Peng Zhang; Sara Pereira Cruz; Kai Zhang; Jing Zhu; Hang-Mao Lee; Sufyan Suleman; Nikolaos Giannareas; Song Liu; Teuvo L J Tammela; Anssi Auvinen; Xiaoyue Wang; Qilai Huang; Liguo Wang; Aki Manninen; Markku H Vaarala; Liang Wang; Johanna Schleutker; Gong-Hong Wei
Journal:  Cell       Date:  2018-07-19       Impact factor: 41.582

9.  Comprehensive Mapping of Pluripotent Stem Cell Metabolism Using Dynamic Genome-Scale Network Modeling.

Authors:  Sriram Chandrasekaran; Jin Zhang; Zhen Sun; Li Zhang; Christian A Ross; Yu-Chung Huang; John M Asara; Hu Li; George Q Daley; James J Collins
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

10.  e-MutPath: computational modeling reveals the functional landscape of genetic mutations rewiring interactome networks.

Authors:  Yongsheng Li; Brandon Burgman; Ishaani S Khatri; Sairahul R Pentaparthi; Zhe Su; Daniel J McGrail; Yang Li; Erxi Wu; S Gail Eckhardt; Nidhi Sahni; S Stephen Yi
Journal:  Nucleic Acids Res       Date:  2021-01-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.